Showing posts with label Nephrogenic Systemic Fibrosis Disappeared After Restrictive Use of Gadolinium?. Show all posts
Showing posts with label Nephrogenic Systemic Fibrosis Disappeared After Restrictive Use of Gadolinium?. Show all posts

Nephrogenic Systemic Fibrosis Disappeared After Restrictive Use of Gadolinium?


According to a large (50 000+) retrospective cohort of patients who underwent contrast-enhanced MR examinations at a single academic institution pre- and post-adoption of strict gadolinium guidelines:-
  • No new cases of nephrogenic systemic fibrosis (NSF) were diagnosed
  • During the pre-guidelines adoption and transitional period, the incidence of NSF was 3 cases per 10,000 contrast-enhanced MRI
  • After the adoption of guidelines, the incidence was 0 per all examinations
The Guidelines for Imaging Adult Patients
  • Based on renal disease severity
  • eGFR 60 or greater - GBCA can be administered as indicated
  • eGFR 30-59 - weight-based dose of GBCA (0.2 mL/kg) can be administered with maximal dose of 20 mL allowed within 24 hours
  • eGFR less than 30 - GBCA cannot be administered except in cases of medical necessity; informed consent required; nephrology consultation required; hemodialysis should be considered
  • Very rarely that any patients with eGFR less than 30 would get contrast-enhanced MR exams (36 in 52 954 exams; 0.07%)
eGFR = estimated glomerular filtration rate; GBCA = gadolinium-based contrast agent

Popular Posts